Cargando…

GLP-1 Based Combination Therapy for Obesity and Diabetes

Detalles Bibliográficos
Autores principales:	Lee, Young Hee, Lee, Hee Won, Choi, Hyung Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for the Study of Obesity 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484915/ https://www.ncbi.nlm.nih.gov/pubmed/31089512 http://dx.doi.org/10.7570/jomes.2017.26.3.155

Ejemplares similares

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
por: Lee, Young-Sun, et al.
Publicado: (2016)

GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You
por: Butler, Peter C., et al.
Publicado: (2010)

Glucolipotoxicity and GLP-1 secretion
por: Hong, Jung-Hee, et al.
Publicado: (2021)

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
por: Yu, Ji Hee, et al.
Publicado: (2022)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Depression and Mortality in Type 2 Diabetes Mellitus
por: Lee, Seo Young, et al.
Publicado: (2017)

Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes
por: Wong, Gunther, et al.
Publicado: (2023)

Special Issue: Resistance to Targeted Therapies in Human Cancer
por: Lee, Tae-Won, et al.
Publicado: (2023)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

GLP-1 physiology informs the pharmacotherapy of obesity
por: Drucker, Daniel J.
Publicado: (2021)

The Latest Insights into Adipokines in Diabetes
por: Kim, Won Kon, et al.
Publicado: (2019)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice
por: Lee, Jeonghoon, et al.
Publicado: (2020)

GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
por: Tanday, Neil, et al.
Publicado: (2021)

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1
por: Sarker, Mithun Kumer, et al.
Publicado: (2020)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
por: Patel, Dhiren
Publicado: (2020)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Do GLP-1–Based Therapies Increase Cancer Risk?
por: Nauck, Michael A., et al.
Publicado: (2013)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Combination of Obesity and High-Fat Feeding Diminishes Sensitivity to GLP-1R Agonist Exendin-4
por: Duca, Frank A., et al.
Publicado: (2013)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans
por: Heni, Martin, et al.
Publicado: (2015)

Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?
por: Marx, Nikolaus, et al.
Publicado: (2018)

Diagnosing Diabetes with Hemoglobin A1c: Current Debates and Considerations for Anemic Patients
por: Kim, Tae Hyuk, et al.
Publicado: (2013)

Diabetes-Associated Common Genetic Variation and Its Association With GLP-1 Concentrations and Response to Exogenous GLP-1
por: Smushkin, Galina, et al.
Publicado: (2012)

Olfactory Receptor OR51E1 Mediates GLP-1 Secretion in Human and Rodent Enteroendocrine L Cells
por: Han, Ye Eon, et al.
Publicado: (2018)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
por: de Boer, Stefanie Amarens, et al.
Publicado: (2015)

Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity
por: Osinski, Céline, et al.
Publicado: (2020)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_neifsle5andc2chjhfuog8p88u